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We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated
intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6–18 months
old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 105 plaque-forming units of each per
0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not
different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the
shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45
vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-
cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and
antibody responses were similar between the monovalent groups and the combination group. Combined RSV/
PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
Respiratory syncytial virus (RSV) is the most important
respiratory viral pathogen of infancy and childhood [1–
3]. Most primary RSV infections are symptomatic [4, 5];
many RSV infections manifest as bronchiolitis and/or
pneumonia, and severe infections occur in younger in-
fants, with peak incidence of lower respiratory-tract dis-
ease (LRI) occurring in infants 2–6 months old, but a
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substantial portion of serious RSV illness and hospital-
ization still occurs in children 16 months old [6–9].
Human parainfluenza viruses (PIVs) are also im-
portant causes of serious respiratory-tract diseases in
infants and young children !5 years old [10–12]. Ac-
cording to the Institute of Medicine, 25% of children
!5 years old will have a clinically significant PIV in-
fection annually, and ∼2% will require hospitalization,
most commonly for croup [12]. PIV is an important
cause of or cofactor in acute otitis media (AOM) in
children. Type 3 PIV (PIV3) is of particular significance
in that, in addition to causing croup and bronchitis, it
ranks second only to RSV as a cause of bronchiolitis
and pneumonia in infants !6 months old. The virus
causes severe disease throughout the first 2 years of life,
and virtually all children have had primary PIV3 in-
fections by 3–4 years of age. Overall, PIV3 is considered
to be responsible for ∼11% of hospitalizations for pe-
diatric respiratory disease [11].
Significant progress is being made in developing live,
attenuated intranasally (inl) administered vaccines for
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influenza, RSV, and PIV3 [13–17]. A cold-passage, tempera-
ture-sensitive strain of RSV (designated cpts-248/404) and a
cold-passage, temperature-sensitive strain of PIV3 (designated
-cp45) have been separately evaluated in phase 1 clinical trials
in seronegative children 6–36 months old [15, 16]. Among
children 16 months old, both vaccines were well tolerated and
immunogenic at doses of 105 pfu and showed evidence of in-
fection with vaccine virus (by isolation of virus and/or increase
in antibody level) in 175% of children who were given inl
vaccine [14, 16]. In studies of infants !6 months old who
received 2 doses of PIV3-cp45 vaccine, there was evidence that
the first dose provided some protection from shedding of vac-
cine virus after the second dose was administered, 1 month
later [15]. Studies with PIV3-cp45 vaccine are progressing in
infants [15], and a phase 2 study in 388 children 6–18 months
old has confirmed the safety of this vaccine candidate for se-
ronegative subjects [14]. The RSV candidate vaccine cpts-248/
404 was evaluated in infants 4–12 weeks old and was found to
cause nasal congestion that interfered with breast-feeding;
therefore, additional attenuating mutations are being intro-
duced into the vaccine [16]. However, for children 16 months
old, RSV cpts-248/404 deserves further study.
In practice, it would be efficient to be able to administer
these vaccines simultaneously. The present report summarizes
the results of a phase 1 study evaluating the simultaneous ad-
ministration of the RSV and PIV3 vaccines, each at a dose of
105 pfu, combined before inl administration. The objectives of
the study were to (1) describe the infection rate, magnitude,
and duration of shedding of RSV and PIV3 after 1 dose of a
combined RSV/PIV3 vaccine administered inl; (2) determine
the tolerability and safety of a combined RSV/PIV3 vaccine;
(3) determine whether interference occurs when RSV and PIV3
are administered simultaneously; and (4) describe the antibody
response as measured in serum and nasal-wash specimens.
SUBJECTS, MATERIALS, AND METHODS
Vaccines
The preparation and derivation of the RSV cpts-248/404 vac-
cine, a derivative of the A2 strain of RSV (subgroup A), and
the PIV3-cp45 vaccine have been described elsewhere [15, 16].
RSV cpts-248/404 vaccine was prepared by Wyeth Vaccines at
a titer of pfu/mL. To achieve the planned dose for61 10
inoculation, this virus suspension was diluted in PBS with su-
crose-phosphate-glutamate (PBS-SPG) to a titer of pfu/54 10
mL. PIV3-cp45 vaccine was prepared by Wyeth Vaccines at a
titer of pfu/mL. Vaccine was diluted in PBS-SPG to a61 10
titer of pfu/mL.54 10
Combination vaccine was made by mixing equal volumes of
the diluted monovalent vaccine, which resulted in titers of 2105
pfu/mL for each vaccine strain. A dose, administered as 0.5-mL
inl drops, delivered 105 pfu of each vaccine virus (RSV cpts-248/
404 and PIV3-cp45). Monovalent vaccines were diluted to a titer
of pfu/mL, which resulted in a dose of 1105 pfu/0.552 10
mL of nasal drops. Placebo consisted of PBS-SPG.
Study Design
The study was a multicenter, randomized, double-blinded com-
parison of bivalent vaccine, monovalent RSV cpts-248/404 vac-
cine, monovalent PIV3-cp45 vaccine, and placebo. Approx-
imately 60 children, 6–18 months old, who were doubly
seronegative for RSV and PIV3, were randomized in a 2:1:1:
1 ratio to receive 1 of the following regimens: RSV cpts-248/
404 and PIV3-cp45 combination vaccine (24 children), RSV
cpts-248/404 monovalent vaccine (12 children), PIV3-cp45
monovalent vaccine (12 children), or placebo (12 children).
Study Subjects
Healthy children 6–18 months old whose parent(s) or guard-
ian(s) gave informed consent to participate were enrolled. Chil-
dren who were seronegative for RSV (defined as neutralizing
antibody titer !1:40) and for PIV3 (defined as a hemaggluti-
nation inhibition [HAI] antibody titer 1:8) were selected.
Children were screened by medical history and physical ex-
amination, to ensure that they had normal health and devel-
opment. The human experimentation guidelines of the US De-
partment of Health and Human Services and those of the
authors’ institutions were followed in the conduct of this clin-
ical research.
Children were excluded if they had known or suspected im-
pairment of immunological function or were receiving im-
munosuppressive therapy. Conditions for exclusion included
systemic corticosteroid therapy, major congenital malforma-
tions, cytogenic abnormalities or serious chronic disorders, car-
diac or respiratory illness, and any prior episode of wheezing
confirmed by a physician (including illnesses diagnosed as
asthma, wheezing, or reactive airway disease, whether attributed
to environmental agents such as allergens or exposure to chem-
ical irritants or to physical agents such as exercise- or cold-
induced asthma, or infection). Also excluded were children with
tympanostomy tubes and members of a household that con-
tained a pregnant woman or an infant !6 months old or any
immunocompromised individual. Children who attended day
care and were in contact with infants !6 months old were
excluded. They were also excluded if they exhibited a current
febrile (temperature, 38C) or other acute illness, including
upper or lower respiratory symptoms (including nasal conges-
tion that was considered significant enough to reduce the like-
lihood of successful immunization) or AOM at the time of
enrollment. Infants born at !37 weeks gestation were deferred
from study participation until they were at least 1 year old.
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Procedures
Serum samples were obtained before inl vaccination and tested
for antibody to RSV and PIV3, to select doubly seronegative
children. Seronegative children were randomized to receive ei-
ther a vaccine or the placebo by nose drops in a volume of
0.25 mL/nostril, for a total dose of 0.5 mL. The parents were
asked to keep track of any illness or symptoms on a parent
diary card each day for 14 days after vaccination and whenever
the child felt warm during the 42-day postvaccine study period.
Children were examined by study personnel, and nasal-wash
samples were collected for the quantitation and phenotyping
of shed virus on days 3–7, 8 or 9, 10, 12, 14, 17 or 18, and 28
after vaccination. These brief visits (20–30 min each) allowed
the study staff to examine the child closely for any signs of a
rhinorrhea, pharyngitis, fever, cough, respiratory illness, or ear
infections. Six weeks after the first vaccination visit, all enrolled
children returned to the clinic for a brief physical examination
and a blood sample and nasal wash to measure antibody re-
sponses to vaccination.
Fever (rectal temperature,38C), upper respiratory-tract ill-
ness (rhinorrhea or pharyngitis), cough, and LRI were defined
as described elsewhere [17]. AOM was defined as findings of
inflamed, immobile tympanic membrane, with or without bulg-
ing, observed by a physician or nurse practitioner and confirmed
by tympanometry or by a second observer. All children were
examined at the end of the study, on days 35–49 after vaccination.
In the event of acute respiratory illness, additional nasal-
wash samples were obtained and cultured for RSV, PIV3, and
a variety of other common respiratory viruses, to help deter-
mine illness etiology. The nursing assessment completed during
these visits included review of the diary card and transcription
of the information, to determine the occurrence of any adverse
events. A postimmunization blood sample and a nasal-wash
sample were obtained from each child on day ∼42 (7 days)
after immunization.
Laboratory Methods
Serum antibody response. Serum samples collected before
and ∼6 weeks after vaccination were evaluated for the presence
of antibody to RSV and PIV3. Antibody to RSV was measured
by the plaque reduction neutralization (PRN) assay, as de-
scribed elsewhere [18]. Antibody to PIV3 was assessed by the
HAI and by ELISA (IgA and IgG) to purified hemagglutinin-
neuraminidase (HN) protein, as described elsewhere [19, 20].
Nasal-wash antibody response. Nasal-wash samples were
evaluated by kinetic ELISA, as described elsewhere [21, 22], to
determine the antibody response to RSV (glycoproteins F and
Ga—i.e., the G attachment protein of RSV subgroup A) and
to PIV3 (purified HN protein). The IgA concentration (in mi-
crograms per milliliter) was determined similarly by use of a
capture method. An increase in the ratio of 4 when prevac-
cination samples were compared with postvaccination samples
from a child or seroconversion from 0 to any value was con-
sidered to be an increase in the level of nasal-wash antibody.
Vaccine virus quantitation and genetic stability. Vaccine
virus shedding levels and temperature-sensitive (ts) phenotypic
stability were determined from fresh or frozen nasal-wash sam-
ples by plaque assay. For the quantitation of RSV in nasal-wash
samples, it was necessary to neutralize any PIV3 that might be
present in the sample, to prevent any PIV3 cytopathic effect
(CPE) from obscuring RSV plaques. Each sample to be tested
for RSV was incubated for 1 h at 32C in the presence of 5%
anti-PIV3 horse serum, then serial 10-fold dilutions of PIV3-
neutralized samples were inoculated onto HEp2 cell monolayers
in duplicate 24-well plates and overlaid with 0.75% methyl-
cellulose in minimum essential medium. The duplicate plates
were incubated for 5 days at 32C for virus quantitation or at
39C for assessment of the ts phenotypic stability of the virus
after replication within the human host. RSV plaques were
stained in an indirect immunoperoxidase (IP) assay by use of
RSV-specific monoclonal antibodies (MAbs) directed against F
and G proteins and horseradish peroxidase (HRP)–labeled goat
anti–mouse IgG, as described elsewhere [23]. Virus titers were
expressed as log10 plaque-forming units per milliliter of nasal-
wash fluid. To determine the ts phenotypic stability of the RSV
recovered from the children, the infectivity titers of virus grown
at 32C and 39C were compared. The ts phenotype of the RSV
present in the sample was considered to be stable if the titer
of RSV detected at 39C was at least 100-fold lower that the
titer of the RSV observed at 32C.
The method to determine the titer and phenotype of the
PIV3 in nasal-wash samples was modified from a plaque assay
described elsewhere [24]. Plaques were visualized by use of
PIV3-specific MAbs and HRP-labeled goat anti–mouse IgG in
an indirect IP assay. Briefly, the agarose plugs were gently re-
moved, and the monolayers were fixed with acetone:methanol
(50%:50%). A mixture of PIV3 MAbs to the HN glycoprotein
was added to each monolayer [25, 26]. After incubation for 1–
2 h at 37C or overnight at 2C–8C, the plates were washed
with PBS, the substrate (Enhance Orange DAB-C/H2O2; Kir-
kegaard and Perry) was added, and the monolayers were incu-
bated on a rocker platform for ∼10–15 min at room temperature.
The monolayers were rinsed with tap water and air-dried, and
plaques were enumerated.
The genetic stability of PIV3 vaccine virus was assessed by
measuring the ts phenotype of the shed virus in original nasal-
wash samples at 39C. Duplicate monolayers of LLC-MK2 cells
were inoculated with test sample; 1 set was incubated at 32C,
and the other set was incubated at 39C. The former was used
to determine the titer of PIV3 shed by each child, and the latter
was used to ascertain the genetic stability of the PIV3 being
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recovered from the nasal-wash samples. The duration of viral
shedding was defined as the last day of vaccine virus detection.
Diagnostic virologic testing on nasal-wash samples obtained
during illness. Children who presented with respiratory symp-
toms during the study provided nasal-wash samples for virus
isolation. Nasal-wash samples were collected and immediately
diluted in 5 virus transport media. The samples were inoculated
onto primary monkey kidney cells, as well as onto at least 2 other
cells lines appropriate for the isolation of common respiratory
viruses, including adenovirus, influenza A and B, PIV 1–4, and
RSV. The tissue-culture cells were incubated at 32C and observed
for CPE for 14 days after inoculation.
If PIV3 was detected in association with illness and the result
did not coincide with the detection of ts virus (vaccine) isolated
from routinely scheduled nasal-wash samples, then the PIV3
isolate was identified by sequence analysis of reverse-transcrip-
tion polymerase chain reaction (RT-PCR) products by use of
primers specific for the amplification of a variable region of
the F gene. The RT-PCR procedure used to detect wild-type
(wt) PIV3 has been described elsewhere [15].
Statistical Analyses
Mean log10 titers of vaccine virus in nasal-wash samples were
calculated for each day tested; nasal-wash samples in which
virus was not detected (minimum amount of virus detectable,
0.7 log10 pfu) were considered to have a titer of 0.4 log10 pfu
for our calculations. Days of virus shedding were compared
between groups by use of the x2 text. Mean virus shedding in
each monovalent group was compared with that in the com-
bination vaccine group by use of analysis of variance (ANOVA).
RESULTS
A surprisingly high proportion of children screened, approxi-
mately one-half, were seronegative for both RSV and PIV3 at 6–
18 months old. As expected, seronegative children tended to be
younger than seropositive children. The average age of enrolled
children was 10 months; 2 children were screened at 18 months
of age but were not vaccinated until 19 months of age; they were
included in the analysis. Fifty-four children were randomized—
21 to the combined RSV cpts-248/404 and PIV3-cp45 group, 9
to placebo, and 12 each to RSV cpts-248/404 or PIV3-cp45 alone.
Shedding of RSV in the monovalent RSV vaccine group (fig-
ure 1A) and the combination vaccine group (figure 1B) was
not significantly different in overall pattern, number of days of
shedding (mean duration of RSV vaccine shedding, 14 days in
the monovalent group and 15 days in the combination group;
table 1), or mean peak titer shed (2.8 vs. 3.4 log10, monovalent
vs. combination group; , ANOVA). In contrast, com-Pp .19
parison of PIV3 shedding in the monovalent PIV3 group (figure
1C) and combination group (figure 1D) revealed modest viral
interference, with PIV3-cp45 shedding in the combination
group, compared with the PIV3 monovalent group. The mean
peak titer of PIV3-cp45 shed was lower (3.8 vs. 2.1 log10, mono-
valent PIV3 vs. combination group; , ANOVA), andPp .01
significantly fewer days of detection of PIV3-cp45 shedding
were found in the combination group. The duration of PIV3-
cp45 shedding (defined as the last day that vaccine virus was
shed) was not significantly different between the 2 groups.
A total of 132 RSV-positive nasal-wash samples from 28
children and 123 PIV3-positive nasal-wash samples from 27
children were tested for ts phenotype. There was no change in
the ts phenotype of RSV or PIV3 vaccine virus detected in
postimmunization nasal-wash samples recovered from children
enrolled in the study (data not shown.) These same samples
contained RSV vaccine titers as high as 6.5 log10 pfu/mL or
PIV3 vaccine titers as high as 5.4 log10 pfu/mL, which indicates
multiple rounds of replication in the human nasopharynx with-
out any change in the ts phenotype.
Clinical events occurring within 14 days of vaccination are
summarized in table 2. LRI was not observed in any study
subject. As expected, some children in the placebo group man-
ifested fever, cough, rhinorrhea, or AOM, and these events
reflect the high background rate of common upper respiratory-
tract illnesses in young children. Although the rates of these
minor illnesses did not differ significantly between vaccinees
and placebo recipients, the study was not powered to examine
the frequency of these events in placebo recipients versus vac-
cinees. However, these results provide background information
for future studies to examine these questions; the sample size
used in the present study has been used elsewhere [15, 16] to
screen vaccine candidates and eliminate highly reactogenic or
overly attenuated vaccines.
Children in the 3 vaccine groups manifested a similar spec-
trum of illnesses as the children who received placebo, with
the possible exception of the occurrence of AOM. Evidence of
AOM was observed in 4 (38%) of 12 children vaccinated with
RSV cpts-248/404 (3/4 children with AOM shed a virus other
than vaccine type, including 1 each of wt PIV, adenovirus, and
influenza virus) and 7 (33%) of 21 children given the com-
bination of RSV cpts-248/404 and PIV3-cp45 vaccines (0/7 shed
a wt virus), compared with 1 (8%) of 12 in the PIV3-cp45
group (this child shed influenza A virus and PIV3-cp45 vaccine)
and 1 (11%) of 9 in the placebo group. However, these rates
were not statistically different. Other manifestations of viral
respiratory disease were common in all study groups, including
cough, rhinorrhea, and fever.
In addition to the concurring viral infections associated with
AOM, as described above, concurrent viral infections were de-
tected in study children and included 1 wt RSV infection in a
child in the monovalent PIV3-cp45 vaccine group and 2 chil-
dren with enterovirus infections in the combination vaccine
group. wt PIV3 was circulating at some of the study sites at
Figure 1. Virus shedding pattern of respiratory syncytial virus (RSV) cpts-248/404 in the monovalent RSV vaccine group (A) vs. the virus shedding pattern of RSV cpts-248/404 in the combination
RSV/parainfluenza 3 virus (PIV3) vaccine group C (B) ( , analysis of variance [ANOVA]). Virus shedding pattern of PIV3-cp45 in the monovalent PIV3 vaccine group (C) vs. the virus shedding patternPp .19
of PIV3-cp45 in the combination RSV/PIV3 vaccine group (D) ( , ANOVA).Pp .01
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Table 1. Mean duration of virus shedding and mean quantity shed on the peak day of virus shedding of respiratory
syncytial virus (RSV) cpts-248/404 or parainfluenza 3 virus (PIV3)–cp45 vaccine among children intranasally given 105 pfu











RSV PIV3 RSV PIV3 RSV PIV3
RSV cpts-248/404 11/12 (92) … 14 0 2.8 !0.5
PIV3-cp45 … 11/12 (92) 0 15 !0.5 3.8
RSV cpts-248/404 and PIV3-cp45 19/21 (90) 16/21 (76) 16 16 3.4 2.1a
Placebo 0/9 1/9c 0 0 !0.5 !0.5
a Significantly more days with no shedding of PIV3-cp45 were seen in the combination group vs. the monovalent PIV3-cp45 group. Duration
of shedding was calculated by use of the last day of virus isolation to indicate the total duration of virus replication.
b Mean virus titer on peak day was calculated by use of the peak titer of virus shed from each child on day 10 for the RSV monovalent
group and on day 7 for the PIV3 monovalent group and the RSV/PIV3 combination group.
c Wild-type PIV3 was isolated from 1 control child.
Table 2. No. of children with the indicated sign or symptom of illness on days 0–14
after intranasal vaccination with respiratory syncytial virus (RSV) cpts-248/404, parain-
fluenza 3 virus (PIV3)–cp45, a combination of both vaccines, or placebo.
Group (no. of children)
Temperature
38C Cough Rhinorrhea LRI AOM
RSV cpts-248/404 (12) 2 7 11 0 4d
PIV3-cp45 (12) 1a 4 8 0 1e
RSV cpts-248/404 and PIV3-cp45 (21) 7b 7c 19 0 7f
Placebo (9) 4 3 5 0 1
NOTE. Data are no. of children. AOM, acute otitis media; LRI, lower respiratory-tract disease.
a One child with temperature 38C shed wild-type (wt) RSV.
b Four children with a temperature 38C shed both RSV and PIV3 (2 of the 4 also shed an enterovirus),
and the other 3 shed only the RSV vaccine phenotype.
c Four children with cough shed RSV and PIV3, 2 shed RSV only, and virus was not isolated from 1.
d Concurrent wt infections occurred in 3 children—1 each of PIV, adenovirus, and influenza virus.
e Concurrent infection with influenza A occurred in this child.
f The children with fever, cough, and/or AOM were not the same 7 children; 14 children had various
combinations of fever and/or cough and/or AOM.
the time of the study, and evidence of concurrent RSV or PIV3
infection was present in the serologic results. Specifically, 2
children in the PIV3 group had antibody increases to RSV, and
antibody increases to PIV3 occurred in 2 children who received
RSV vaccine and in 3 placebo recipients.
Both the RSV and PIV3 vaccine strains induced the pro-
duction of serum and mucosal antibody. The frequency of de-
veloping serum neutralization antibody responses for RSV or
serum HAI antibody responses for PIV3 was not significantly
different in the monovalent groups versus the combination
group (table 3). The RSV vaccine above induced antibody in
9 (90%) of 10 children, and the RSV/PIV3 combination vaccine
induced RSV antibody in 18 (95%) of 19 children. There was
a suggestion that PIV3 immunogenicity was reduced, but this
did not achieve statistical significance; 9 (82%) of 11 children
developed antibody in the monovalent PIV3-cp45 group, com-
pared with 12 (60%) of 20 in the bivalent group ( ).Pp .26
Among those who were infected by a vaccine virus, the post-
vaccine geometric mean PRN antibody titer to RSV or HAI
antibody to PIV3 was not significantly different (table 3, foot-
notes c and d). Nasal-wash antibody responses to RSV for Ga
antigens occurred in 6 (50%) and 8 (67%) of 12 children, re-
spectively, in the monovalent vaccine group and in 7 (33%)
and 14 (67%) of 21 children, respectively, in the combination
vaccine group (table 3). After a single dose of vaccine, nasal-
wash antibody response to PIV3 was found in only 2 (17%)
of 12 children in the monovalent vaccine group and in 6 (29%)
of 21 children in the combination group.
DISCUSSION
The development of a safe and effective vaccine for the prevention
of respiratory disease caused by RSV and PIV3 represents an
important but elusive objective. RSV is the most important cause
of LRI in infants and young children, and it causes significant
disease in elderly and immunocompromised patients. PIV3 is
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Table 3. Development of 4-fold serum and/or nasal-wash antibody responses to respiratory syn-
cytial virus (RSV) or parainfluenza 3 virus (PIV3) among initially seronegative children after vaccination
with RSV cpts-248/404, PIV3-cp45, both vaccines, or placebo.







RSV PIV3 Both RSV F RSV Ga PIV3 Both
RSV cpts-248/404 (12) 9/10 2/11a 1/10a 6/12 8/12 1/12 0/12
PIV3-cp45 (12) 2/12a 9/11b 2/11a 3/12 1/12 2/12 0/12
RSV cpts-248/404 and PIV3-cp45 (21) 18/19c 12/20b,d 11/18 7/21 14/21 6/21 5/21
Placebo (9) 0/5 3/9a 0/5 2/8 0/8 3/8 0/8
NOTE. Seronegative to RSV, serum neutralizing antibody titer !1:40; seronegative to PIV3, serum hemagglutination
inhibition (HAI) antibody 1:8.
a Wild-type RSV unexpectedly circulated in the community, and PIV3 was endemic, as expected.
b Nine of 11 vs. 12 of 20 ( ).Pp .26
c Among those who were infected with RSV vaccine-type virus, as indicated by shedding of RSV cpts-248/404 or 4
fold antibody increase to RSV, the log mean postvaccine neutralizing antibody to RSV was not significantly different in
the monovalent vs. combination group, vs. . Geometric mean titers were 504 and 276, respectively.8.81.1 8.11.0
d Among those who were infected with PIV3 vaccine virus, as indicated by shedding of PIV3-cp45 or 4 fold antibody
increase to PIV3, the log mean postvaccine HAI titer to PIV3 was not significantly different in the monovalent vs.
combination group, (SD) vs. ; geometric mean HAI antibodies were 17 vs. 12, respectively.4.11.7 3.62.0
the second most important cause of bronchiolitis and pneumonia
during the first 6 months of life and is a common cause of febrile
respiratory disease and AOM in older children. Recent experience
with a cold-adapted, ts, attenuated influenza vaccine adminis-
tered by the inl route demonstrated the feasibility of this tech-
nology for vaccine administration [13].
Several key issues in developing a bivalent RSV-PIV3 vaccine
were addressed in the present pilot study. We sought to develop
preliminary observations to assess whether combined vaccine
would exhibit evidence of augmented reactogenicity. RSV and
PIV3 frequently are involved in dual or mixed viral infections
that occur in ∼15% of respiratory illnesses in the community
[27–30]. In general, the clinical syndromes associated with dual
respiratory viral infections have appeared to be indistinguish-
able from single-agent infections, although one review [29]
found that dual infections may be more severe and were more
likely to result in hospitalization. Additionally, evidence of viral
interference or decreased immunogenicity was sought to de-
termine a preliminary strategy for the vaccination of children
against both diseases.
The present results suggest that bivalent RSV/PIV3 vaccine
is feasible to develop. A majority of children in the bivalent
vaccine group responded to both the RSV and PIV vaccine
components. The present results demonstrate only very modest
interference by RSV with the PIV component. A simple strategy
to overcome this interference would be to give 2 doses separated
by an appropriate interval, to be determined by clinical inves-
tigations—a 2-month interval was successful with live, atten-
uated trivalent inl influenza vaccine. In previous studies in this
age group [16], the RSV cpts-248/404 vaccine appeared to be
satisfactorily attenuated, but it retained some reactogenicity in
infants !6 months old. As a test-of-concept study, the acute
safety of the combined RSV-PIV3 vaccine could not be differ-
entiated from those of either monovalent vaccine or placebo.
Although no significant differences were observed, the clinical
events associated with the RSV component of bivalent vaccine
may be significant, but confirmation of this observation will
require a larger study, given the high frequency of concurrent
virus infections in this age group.
Peak virus shedding titers in the monovalent RSV cpts-248/
404 vaccine group were higher than have been previously re-
ported [16]; the higher titers in the present study reflect a
change in the laboratory assessment methods. In the present
study, IP staining of plaques was used to determine titers,
whereas, elsewhere, plaque assay without IP was used. Similarly,
peak virus shedding titers in the monovalent PIV3-cp45 vaccine
group were higher than those reported elsewhere because of
our use of an IP stain to determine plaque count [15, 17].
The characteristics of PIV3-cp45 vaccine appear to be suitable
for expanded trials. Recently, a phase 2 study was completed in
380 children 6–18 months old. No increase in rhinorrhea, cough,
fever, or AOM was found when these findings were compared
in seronegative, vaccinated recipients versus placebo control sub-
jects. PIV3-cp45 vaccine induced vigorous HAI antibody re-
sponses (geometric mean titer [GMT], 1:24 after vaccination)
that were within ∼2-fold of the antibody level found in naturally
infected children before vaccination (GMT, 1:50).
Genetic stability was assessed, and the vaccine viruses re-
tained their ts phenotype, despite multiple cycles of replication
in young seronegative children; the multiple genetic changes
introduced into PIV3-cp45 and RSV cpts-248/404 provide a
good means of safety to ensure that viruses with a virulent
phenotype will not emerge during replication in children.
Significant progress is being made toward further attenuation
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of the RSV component. Once a suitable RSV vaccine compo-
nent is derived, it can be combined with PIV3-cp45 vaccine
and evaluated for the safety, infectivity, and efficacy of each
component. The present study has provided a rationale and a
model protocol for proceeding with those future evaluations.
The RSV cpts-248/404 component interfered with PIV3-cp45,
but not the reverse; this suggests that further attenuated de-
rivatives of RSV cpts-248/404 might not interfere or would
interfere to a lesser degree and, therefore, would work well in
combination with PIV3-cp45, but this will need to be tested
in clinical trials and determined empirically. The results of the
present test-of-concept trial provide the framework for future
development of bivalent RSV/PIV3 vaccine.
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